Physician
New York City Health and Hospitals Corporation
New York City Health and Hospitals Corporation was paid $107.34M by Medicaid between Jan 2018 and Dec 2024, across 503 billing codes. Its largest line is 99283, emergency room visit (moderate) — 12% of everything it billed.
33Billing provider infoNEW YORK CITY HEALTH AND HOSPITALS CORPORATION
BROOKLYN, NY 11235
BROOKLYN, NY 11235
33aNPI1124032982assigned 07/28/2006
33bProvider typeInternal Medicine Physician
28Total paid$107.34M
24GClaims2,444,055
24DCodes billed503
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Internal Medicine Physician providers in New York
Rank by total paid#9 of 6,049
Median peer was paid$11K
This provider vs. median9,489×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official KARLIN, MARJI controls 19+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 40,510 | $239K | |
| 2019 | 157,580 | $6.13M | |
| 2020 | 371,677 | $17.50M | |
| 2021 | 696,526 | $29.53M | |
| 2022 | 556,618 | $25.14M | |
| 2023 | 323,253 | $14.37M | |
| 2024incomplete | 297,891 | $14.44M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 70,125 | 63,626 | $13.13M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 9.6% | 143,462 | 121,621 | $10.27M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.8% | 97,863 | 80,512 | $8.36M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.5% | 36,195 | 31,290 | $6.99M |
| 36415 | Collection of venous blood by venipuncture | 4.5% | 299,261 | 99,236 | $4.82M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.8% | 19,825 | 18,151 | $4.05M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3.5% | 33,992 | 29,844 | $3.81M |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.0% | 43,788 | 15,138 | $3.18M |
| G0378 | Hospital observation service, per hour | 2.7% | 2,642 | 2,280 | $2.87M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 2.2% | 130,364 | 108,192 | $2.35M |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 1.8% | 13,711 | 9,151 | $1.88M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.6% | 8,984 | 8,517 | $1.67M |
491 more codes
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.5% | 21,548 | $1.63M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.5% | 6,217 | $1.58M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.4% | 65,444 | $1.50M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.3% | 22,239 | $1.44M |
| J2426 | Injection, paliperidone palmitate extended release (invega sustenna), 1 mg | 1.2% | 1,098 | $1.30M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.0% | 43,678 | $1.11M |
| 90834 | Psychotherapy session, about 45 minutes | 1.0% | 5,731 | $1.10M |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 8,182 | $1.03M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 7,889 | $925K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 8,614 | $844K |
| J0401 | Injection, aripiprazole (abilify maintena), 1 mg | <1% | 852 | $837K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 10,021 | $813K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 5,445 | $793K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 6,970 | $757K |
| 86480 | <1% | 13,352 | $747K | |
| H0040 | Assertive community treatment program, per diem | <1% | 542 | $701K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 3,491 | $694K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 14,888 | $677K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,780 | $660K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 4,145 | $656K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 16,532 | $636K |
| 99442 | <1% | 7,571 | $562K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 12,996 | $530K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,537 | $503K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 6,856 | $476K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 35,602 | $443K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 2,752 | $436K |
| D9999 | Unspecified adjunctive procedure, by report | <1% | 3,138 | $427K |
| 80053 | Comprehensive metabolic panel | <1% | 33,685 | $418K |
| H0001 | Alcohol and/or drug assessment | <1% | 2,509 | $414K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 944 | $410K |
| 99443 | <1% | 3,273 | $356K | |
| H0004 | Behavioral health counseling and therapy, per 15 minutes | <1% | 5,887 | $351K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,721 | $347K |
| D0999 | Unspecified diagnostic procedure, by report | <1% | 2,136 | $341K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 11,367 | $341K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 2,690 | $340K |
| 76818 | <1% | 2,768 | $331K | |
| 76770 | <1% | 1,331 | $321K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 21,200 | $319K |
| 99205 | Prolong outpt/office vis | <1% | 1,550 | $305K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 3,089 | $304K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,577 | $260K |
| 86850 | <1% | 10,646 | $259K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 15,012 | $254K |
| 12001 | <1% | 731 | $245K | |
| 81408 | <1% | 212 | $244K | |
| 85027 | <1% | 79,957 | $242K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 8,717 | $242K |
| 12011 | <1% | 746 | $240K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 9,805 | $237K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 22,937 | $221K |
| 99201 | <1% | 2,022 | $220K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 4,715 | $212K |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | <1% | 2,652 | $209K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,010 | $208K |
| 76641 | <1% | 1,655 | $207K | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 287 | $202K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,537 | $202K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,914 | $196K |
| H0002 | Behavioral health screening to determine eligibility for admission to treatment program | <1% | 1,044 | $194K |
| 80061 | Lipid panel | <1% | 18,379 | $193K |
| 0002A | <1% | 6,149 | $191K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 19,227 | $190K |
| 93970 | <1% | 542 | $182K | |
| 86901 | <1% | 10,812 | $179K | |
| 0001A | <1% | 6,319 | $179K | |
| J2315 | Injection, naltrexone, depot form, 1 mg | <1% | 151 | $169K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 764 | $163K |
| 96161 | <1% | 9,966 | $161K | |
| 70486 | <1% | 1,291 | $160K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 230 | $157K |
| 80076 | <1% | 21,968 | $157K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 21,731 | $152K |
| 86703 | <1% | 11,777 | $152K | |
| 99441 | <1% | 3,251 | $146K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,683 | $143K |
| 87486 | <1% | 5,513 | $141K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,438 | $139K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 6,057 | $137K |
| 90461 | <1% | 10,011 | $132K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 5,214 | $130K |
| 97802 | <1% | 2,837 | $128K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 684 | $128K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 10,966 | $128K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 974 | $124K |
| 83655 | <1% | 11,012 | $123K | |
| 90677 | <1% | 1,274 | $122K | |
| 86900 | <1% | 10,780 | $122K | |
| 59025 | Fetal non-stress test | <1% | 816 | $121K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 709 | $121K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 19,982 | $121K |
| 84703 | <1% | 27,269 | $113K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 170 | $113K |
| 90651 | <1% | 1,272 | $108K | |
| 90715 | <1% | 4,498 | $108K | |
| 85610 | <1% | 20,809 | $106K | |
| 99381 | <1% | 2,472 | $101K | |
| 87581 | <1% | 5,514 | $100K | |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 589 | $97K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,432 | $91K |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 2,298 | $89K |
| 82805 | <1% | 8,680 | $88K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 11,641 | $85K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,860 | $85K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,814 | $84K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,564 | $83K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 498 | $81K |
| 0004A | <1% | 1,991 | $77K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 1,002 | $76K |
| D2335 | <1% | 279 | $74K | |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | <1% | 73 | $73K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,228 | $71K |
| 90686 | <1% | 7,834 | $71K | |
| 76820 | <1% | 1,409 | $70K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,078 | $70K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,311 | $69K |
| H0050 | Alcohol and/or drug services, brief intervention, per 15 minutes | <1% | 1,498 | $69K |
| 86769 | <1% | 1,994 | $65K | |
| 90750 | <1% | 855 | $65K | |
| 86780 | <1% | 7,425 | $65K | |
| 76536 | <1% | 528 | $64K | |
| 87536 | <1% | 679 | $63K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,926 | $63K |
| 84439 | <1% | 10,198 | $63K | |
| 83880 | <1% | 3,524 | $62K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,097 | $59K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 209 | $58K |
| T1013 | Sign language or oral interpretive services, per 15 minutes | <1% | 6,275 | $57K |
| 86803 | <1% | 5,681 | $56K | |
| 82607 | <1% | 4,839 | $55K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 665 | $53K |
| 90746 | <1% | 1,004 | $53K | |
| 97803 | <1% | 1,069 | $53K | |
| 87800 | <1% | 1,609 | $52K | |
| 12002 | <1% | 148 | $52K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 923 | $50K |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | <1% | 628 | $50K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 174 | $47K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 1,620 | $45K |
| 76801 | <1% | 346 | $45K | |
| 73630 | <1% | 2,620 | $45K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 13,499 | $43K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 84 | $43K |
| 88142 | <1% | 1,795 | $41K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 489 | $41K |
| 97014 | <1% | 2,271 | $41K | |
| 81001 | <1% | 29,018 | $39K | |
| 90670 | <1% | 2,678 | $39K | |
| 96127 | <1% | 11,741 | $38K | |
| 80320 | <1% | 13,370 | $38K | |
| 84702 | <1% | 6,864 | $38K | |
| 86360 | <1% | 801 | $37K | |
| 87340 | <1% | 5,057 | $37K | |
| 81329 | <1% | 305 | $37K | |
| D7250 | <1% | 250 | $36K | |
| 29125 | <1% | 172 | $35K | |
| 73564 | <1% | 1,720 | $35K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 164 | $35K |
| 72100 | <1% | 1,560 | $34K | |
| 90697 | <1% | 1,399 | $33K | |
| 73610 | <1% | 2,209 | $33K | |
| H0049 | Alcohol and/or drug screening | <1% | 695 | $33K |
| 96367 | <1% | 996 | $33K | |
| 0072A | <1% | 779 | $32K | |
| 0071A | <1% | 817 | $31K | |
| 86359 | <1% | 795 | $30K | |
| 90680 | <1% | 2,534 | $30K | |
| 71045 | Radiologic examination, chest; single view | <1% | 5,116 | $30K |
| 83970 | <1% | 873 | $30K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 366 | $30K |
| 82728 | <1% | 2,979 | $29K | |
| 81161 | <1% | 182 | $28K | |
| 97162 | <1% | 249 | $28K | |
| 76000 | <1% | 229 | $27K | |
| 73110 | <1% | 1,892 | $27K | |
| 86762 | <1% | 2,419 | $26K | |
| 97010 | <1% | 2,886 | $25K | |
| G0397 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and intervention, greater than 30 minutes | <1% | 146 | $25K |
| 88312 | <1% | 268 | $25K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 101 | $24K |
| 81003 | <1% | 13,423 | $24K | |
| 77066 | Tomosynthesis, mammo | <1% | 149 | $24K |
| 73030 | <1% | 1,644 | $24K | |
| 86706 | <1% | 2,909 | $23K | |
| 86765 | <1% | 2,425 | $23K | |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 154 | $23K |
| 82948 | <1% | 17,397 | $23K | |
| 82951 | <1% | 2,099 | $22K | |
| 86787 | <1% | 2,455 | $22K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 764 | $22K |
| 88304 | <1% | 774 | $21K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 4,130 | $21K |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 76 | $20K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,152 | $20K |
| 83550 | <1% | 3,089 | $19K | |
| 84153 | <1% | 1,367 | $19K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 96 | $19K |
| 86735 | <1% | 2,037 | $19K | |
| 87081 | <1% | 5,213 | $18K | |
| 81405 | <1% | 92 | $18K | |
| 93971 | <1% | 240 | $18K | |
| 73130 | <1% | 1,637 | $17K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 177 | $16K |
| 82105 | <1% | 1,375 | $16K | |
| 85730 | <1% | 10,286 | $16K | |
| 80356 | <1% | 3,309 | $16K | |
| 83540 | <1% | 3,402 | $16K | |
| 76870 | <1% | 232 | $15K | |
| 90633 | <1% | 1,260 | $15K | |
| 90707 | <1% | 691 | $15K | |
| 83020 | <1% | 1,343 | $15K | |
| 82274 | <1% | 1,187 | $14K | |
| D0220 | Intraoral - periapical first radiographic image | <1% | 1,809 | $14K |
| 90716 | <1% | 635 | $14K | |
| J2704 | Injection, propofol, 10 mg | <1% | 4,466 | $13K |
| 81361 | <1% | 109 | $12K | |
| 74018 | <1% | 1,041 | $12K | |
| 82043 | <1% | 2,676 | $12K | |
| 77062 | <1% | 77 | $11K | |
| 0124A | <1% | 260 | $11K | |
| 97165 | <1% | 97 | $11K | |
| 86141 | <1% | 3,248 | $11K | |
| 83735 | <1% | 12,291 | $11K | |
| 73502 | <1% | 531 | $11K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 11,650 | $10K |
| 81025 | <1% | 2,249 | $10K | |
| 84146 | <1% | 600 | $10K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 16,279 | $10K |
| 45300 | <1% | 27 | $10K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 970 | $10K |
| 90698 | <1% | 813 | $10K | |
| 90723 | <1% | 958 | $10K | |
| 73090 | <1% | 1,068 | $10K | |
| 88141 | <1% | 355 | $10K | |
| 73140 | <1% | 738 | $10K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 13,740 | $10K |
| 82465 | <1% | 2,889 | $10K | |
| 84484 | <1% | 10,737 | $10K | |
| 81401 | <1% | 108 | $9K | |
| 99383 | <1% | 123 | $9K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,045 | $9K |
| D0120 | Dental checkup, returning patient | <1% | 1,179 | $9K |
| 90647 | <1% | 875 | $9K | |
| 81257 | <1% | 134 | $9K | |
| H0038 | Self-help/peer services, per 15 minutes | <1% | 459 | $9K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 7,515 | $9K |
| 90656 | <1% | 688 | $9K | |
| 87186 | <1% | 2,128 | $9K | |
| 97597 | <1% | 25 | $8K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 67 | $8K |
| 73590 | <1% | 846 | $8K | |
| 36430 | <1% | 28 | $8K | |
| 90732 | <1% | 83 | $7K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,921 | $7K |
| 82746 | <1% | 704 | $7K | |
| 92250 | <1% | 134 | $7K | |
| 82248 | <1% | 2,158 | $7K | |
| 83690 | <1% | 10,929 | $7K | |
| D1110 | Prophylaxis - adult | <1% | 530 | $7K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,329 | $7K |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 99 | $7K |
| 83001 | <1% | 403 | $7K | |
| 82677 | <1% | 336 | $6K | |
| 81243 | <1% | 187 | $6K | |
| 88300 | <1% | 730 | $6K | |
| 80354 | <1% | 1,264 | $6K | |
| 80047 | <1% | 401 | $6K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,579 | $6K |
| 74019 | <1% | 367 | $6K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 25 | $6K |
| 99051 | <1% | 672 | $6K | |
| D0140 | Limited oral evaluation - problem focused | <1% | 415 | $6K |
| 82803 | <1% | 2,557 | $6K | |
| 87535 | <1% | 160 | $5K | |
| 3074F | <1% | 27,058 | $5K | |
| 97035 | <1% | 344 | $5K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 3,918 | $5K |
| D1120 | Dental cleaning, child | <1% | 69 | $5K |
| 73080 | <1% | 513 | $5K | |
| 73620 | <1% | 301 | $5K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 61 | $5K |
| 90694 | <1% | 177 | $5K | |
| 82247 | <1% | 1,527 | $5K | |
| 90744 | <1% | 416 | $5K | |
| 51798 | <1% | 29 | $5K | |
| 90620 | <1% | 278 | $4K | |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 198 | $4K |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 1,268 | $4K |
| Q3014 | Telehealth originating site facility fee | <1% | 611 | $4K |
| 95117 | <1% | 304 | $4K | |
| 97026 | <1% | 533 | $4K | |
| 85045 | <1% | 1,477 | $4K | |
| 81400 | <1% | 96 | $4K | |
| 81255 | <1% | 108 | $4K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,193 | $4K |
| 84704 | <1% | 336 | $4K | |
| 90734 | <1% | 153 | $4K | |
| 86336 | <1% | 335 | $4K | |
| 83615 | <1% | 1,503 | $4K | |
| 73562 | <1% | 221 | $4K | |
| 83002 | <1% | 216 | $4K | |
| 85651 | <1% | 1,753 | $4K | |
| 81200 | <1% | 108 | $3K | |
| 81251 | <1% | 108 | $3K | |
| 82570 | <1% | 1,050 | $3K | |
| 97124 | <1% | 98 | $3K | |
| 90648 | <1% | 300 | $3K | |
| 84480 | <1% | 381 | $3K | |
| 86704 | <1% | 369 | $3K | |
| 94010 | <1% | 93 | $3K | |
| 82550 | <1% | 3,578 | $3K | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 42 | $3K |
| 84100 | <1% | 1,500 | $3K | |
| 73120 | <1% | 178 | $3K | |
| 83605 | <1% | 3,474 | $3K | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 1,943 | $3K |
| 90480 | <1% | 88 | $3K | |
| J1631 | Injection, haloperidol decanoate, per 50 mg | <1% | 138 | $3K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 686 | $3K |
| 73600 | <1% | 171 | $3K | |
| T2022 | Case management, per month | <1% | 63 | $3K |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 1,294 | $3K |
| 81260 | <1% | 108 | $3K | |
| 84550 | <1% | 1,000 | $3K | |
| 92002 | <1% | 28 | $3K | |
| 96368 | <1% | 78 | $3K | |
| D1206 | Topical application of fluoride varnish | <1% | 656 | $3K |
| 0003A | <1% | 64 | $3K | |
| 72070 | <1% | 123 | $3K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 64 | $3K |
| 86038 | <1% | 292 | $2K | |
| H2010 | Comprehensive medication services, per 15 minutes | <1% | 28 | $2K |
| 85379 | <1% | 1,841 | $2K | |
| J0290 | Injection, ampicillin sodium, 500 mg | <1% | 427 | $2K |
| 97161 | <1% | 25 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,593 | $2K |
| 0012A | <1% | 111 | $2K | |
| 99382 | <1% | 238 | $2K | |
| D2330 | <1% | 26 | $2K | |
| 86376 | <1% | 162 | $2K | |
| 82330 | <1% | 2,409 | $2K | |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 80 | $2K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 68 | $2K |
| 96160 | <1% | 100 | $2K | |
| 97022 | <1% | 80 | $2K | |
| 85007 | <1% | 1,737 | $2K | |
| 80348 | <1% | 226 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,173 | $2K |
| 82952 | <1% | 278 | $2K | |
| 73070 | <1% | 213 | $2K | |
| 82397 | <1% | 1,690 | $2K | |
| 99404 | <1% | 14 | $2K | |
| 84156 | <1% | 808 | $2K | |
| 90710 | <1% | 97 | $2K | |
| D0145 | Oral evaluation for a patient under three years of age | <1% | 328 | $2K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,278 | $2K |
| 84403 | <1% | 70 | $2K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 192 | $2K |
| 96376 | <1% | 1,638 | $2K | |
| 0011A | <1% | 113 | $2K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 1,979 | $1K |
| 77065 | Tomosynthesis, mammo | <1% | 12 | $1K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,134 | $1K |
| 90700 | <1% | 119 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 708 | $1K |
| J2359 | Injection, olanzapine, 0.5 mg | <1% | 219 | $1K |
| J1741 | Injection, ibuprofen, 100 mg | <1% | 185 | $1K |
| 85384 | <1% | 493 | $1K | |
| 71250 | <1% | 13 | $1K | |
| 92550 | <1% | 29 | $1K | |
| 71101 | <1% | 171 | $1K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 105 | $1K |
| 97116 | <1% | 38 | $1K | |
| D1208 | Topical application of fluoride, excluding varnish | <1% | 175 | $1K |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 2,897 | $1K |
| 87338 | <1% | 118 | $1K | |
| 97168 | <1% | 13 | $1K | |
| 76830 | Ultrasound, transvaginal | <1% | 12 | $1K |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 13 | $1K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,911 | $1K |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 1,001 | $1K |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,511 | $1K |
| 92557 | <1% | 27 | $1K | |
| 73560 | <1% | 59 | $1K | |
| 87040 | <1% | 826 | $987.94 | |
| 80321 | <1% | 99 | $981.42 | |
| 86580 | <1% | 195 | $930.81 | |
| 96380 | <1% | 92 | $926.91 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 108 | $888.33 |
| 90696 | <1% | 72 | $868.25 | |
| D0274 | Bitewings - four radiographic images | <1% | 251 | $860.05 |
| 83516 | <1% | 60 | $841.87 | |
| 91320 | <1% | 56 | $806.01 | |
| 3077F | <1% | 4,103 | $795.00 | |
| 82962 | <1% | 115 | $776.86 | |
| 83527 | <1% | 82 | $767.19 | |
| 82010 | <1% | 852 | $765.10 | |
| 82977 | <1% | 154 | $755.07 | |
| 99401 | <1% | 14 | $751.39 | |
| 76857 | <1% | 16 | $740.50 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 345 | $727.84 |
| 73060 | <1% | 103 | $725.16 | |
| 80051 | <1% | 58 | $687.79 | |
| 90662 | <1% | 31 | $613.80 | |
| 88112 | <1% | 13 | $604.42 | |
| 90381 | <1% | 42 | $603.06 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 712 | $562.42 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 158 | $559.21 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 1,716 | $535.96 |
| 3078F | <1% | 25,692 | $532.73 | |
| 3079F | <1% | 10,680 | $530.00 | |
| 99493 | <1% | 28 | $513.60 | |
| 90685 | <1% | 78 | $499.89 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,817 | $499.35 |
| 92134 | <1% | 12 | $481.05 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 23 | $478.88 |
| 87070 | <1% | 44 | $472.01 | |
| 86140 | <1% | 180 | $458.57 | |
| 0031A | <1% | 16 | $456.22 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 219 | $432.18 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 60 | $421.27 |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 14 | $373.70 |
| 83718 | <1% | 132 | $372.67 | |
| 87420 | <1% | 200 | $360.87 | |
| 90380 | <1% | 22 | $351.44 | |
| 73100 | <1% | 27 | $340.44 | |
| 90661 | <1% | 35 | $312.20 | |
| 92015 | Determination of refractive state | <1% | 14 | $310.70 |
| 80165 | <1% | 51 | $300.41 | |
| 84402 | <1% | 14 | $299.80 | |
| 90653 | <1% | 31 | $294.59 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 2,472 | $293.60 |
| 84478 | <1% | 131 | $291.98 | |
| 86705 | <1% | 55 | $282.68 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 237 | $275.77 |
| 90674 | <1% | 17 | $265.86 | |
| 3075F | <1% | 6,990 | $265.00 | |
| 73552 | <1% | 40 | $256.45 | |
| 87177 | <1% | 26 | $220.72 | |
| 92587 | <1% | 12 | $204.21 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 71 | $180.00 |
| 82378 | <1% | 24 | $157.77 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,043 | $154.67 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 419 | $141.78 |
| 86593 | <1% | 30 | $130.75 | |
| 86255 | <1% | 15 | $127.34 | |
| 82947 | <1% | 68 | $122.14 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 1,241 | $115.12 |
| 99494 | <1% | 13 | $110.34 | |
| 73660 | <1% | 25 | $94.55 | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 57 | $83.45 |
| G0008 | Administration of influenza virus vaccine | <1% | 170 | $63.56 |
| 93793 | <1% | 43 | $62.89 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 61 | $43.70 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 39 | $43.18 |
| 86430 | <1% | 14 | $41.27 | |
| 82150 | <1% | 50 | $41.21 | |
| J1815 | Injection, insulin, per 5 units | <1% | 67 | $40.13 |
| 85014 | <1% | 275 | $39.30 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 99 | $38.24 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 56 | $37.24 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 14 | $33.54 |
| 86708 | <1% | 12 | $27.78 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 15 | $17.30 |
| 83930 | <1% | 15 | $16.19 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 31 | $16.05 |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 12 | $14.57 |
| 87205 | <1% | 14 | $6.97 | |
| 99173 | <1% | 357 | $4.38 | |
| 82553 | <1% | 19 | $3.92 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 30 | $3.78 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 15 | $1.81 |
| J3490 | Unclassified drugs | <1% | 15 | $1.77 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 17 | $0.35 |
| 99499 | 0% | 712 | $0.00 | |
| D0190 | 0% | 317 | $0.00 | |
| 1160F | 0% | 3,556 | $0.00 | |
| D0180 | 0% | 13 | $0.00 | |
| 1159F | 0% | 4,464 | $0.00 | |
| 99408 | 0% | 199 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 31 | $0.00 |
| 99080 | 0% | 639 | $0.00 | |
| D1330 | 0% | 1,154 | $0.00 | |
| 3080F | 0% | 1,729 | $0.00 | |
| 99406 | 0% | 197 | $0.00 | |
| 3044F | 0% | 180 | $0.00 | |
| 1220F | 0% | 990 | $0.00 | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | 0% | 152 | $0.00 |
| 92551 | 0% | 369 | $0.00 | |
| 4293F | 0% | 67 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKARLIN, MARJI (CHIEF REVENUE OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.